The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $112.46, a high ...

Leerink Partners analyst Daina Graybosch maintained a Buy rating on Nkarta (NKTX – Research Report) yesterday and set a price target of $7.00.

Leerink Partners analyst Daina Graybosch maintained a Buy rating on Century Therapeutics (IPSC – Research Report) yesterday and set a price ...

Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.

On Jan. 30, Leerink Partners analyst Daina Graybosch maintained a “Buy” rating on MRK with a price target of $118, implying a potential upside of 18.2% from current levels. The mean price ...

Q4 2024 Management View Rob Davis emphasized Merck's strong performance in 2024, driven by demand for KEYTRUDA, the launch of WINREVAIR, and robust growth in Animal Health. Davis highlighted ...

Daina Graybosch, Leerink Partners: Asked about WINREVAIR’s HYPERION trial outcomes. Dean Li stated the trial was stopped early due to overwhelming efficacy, reinforcing the drug’s ...

Rahway, New Jersey-based Merck & Co., Inc. (MRK) functions as a healthcare company. Valued at $252.4 billion by market cap, the company delivers health solutions through its prescription medicines, ...

Leerink Partnrs analyst D. Graybosch forecasts that the company will post earnings of $11.66 per share for the year. The consensus estimate for Merck & Co., Inc.’s current full-year earnings is ...